Prevalence of Heparin-Induced Thrombocytopenia in Hospitalized Patients With Antiphospholipid Syndrome or Lupus With Antiphospholipid Antibodies

抗磷脂综合征或伴有抗磷脂抗体的狼疮住院患者中肝素诱导的血小板减少症的患病率

阅读:4

Abstract

OBJECTIVE: This study aims to investigate the prevalence of heparin-induced thrombocytopenia among hospitalized patients with antiphospholipid syndrome or systemic lupus erythematosus with antiphospholipid antibodies. METHODS: A retrospective cohort study was performed on patients hospitalized at a tertiary care medical center who met criteria for antiphospholipid syndrome or lupus with antiphospholipid antibodies and were evaluated for heparin-induced thrombocytopenia with anti-platelet factor 4 or serotonin release assay. Pretest probabilities of heparin-induced thrombocytopenia were estimated using a 4T score. Proportions of patients with positive anti-platelet factor 4 and serotonin release assay tests were calculated, and the number of patients meeting clinical criteria for heparin-induced thrombocytopenia was determined. RESULTS: Of 33 patients identified in screening, 23 met inclusion criteria. Pretest probability for heparin-induced thrombocytopenia based on 4T scores was intermediate in 9 (39%) and high in no patients. Only 1 patient (4%) tested positive for anti-platelet factor 4. Serotonin release assay was tested in 4 patients (17%) and was negative in all cases. CONCLUSION: Among 23 hospitalized patients with antiphospholipid syndrome or lupus with antiphospholipid antibodies who were tested, none were diagnosed with heparin-induced thrombocytopenia. Most patients had low pretest probability for heparin-induced thrombocytopenia based on 4T scores but were still tested for anti-platelet factor 4. Our study suggests that heparin-induced thrombocytopenia is rare among hospitalized patients with antiphospholipid syndrome or lupus with antiphospholipid antibodies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。